The presence of a huge population over the age of 60, with lower immunity levels and a higher risk of PAH and related illnesses, is a significant impact-rendering driver for the PAH (Pulmonary Arterial Hypertension) market’s growth throughout the projection period. Even though PAH has a 45-year onset age, it is commonly seen in people beyond 60. This demographic is anticipated to receive the finest therapies available, extending their lives. This might be a potential target population for PAH medicines, which is driving increased demand.

New product development, partnerships, and regional expansion are some of the key strategies used by industry players to gain a strong footing in the market. For example, Johnson & Johnson paid USD 6.5 billion for Momenta Pharmaceuticals, Inc. in October 2020. J&J’s position in the autoimmune disorders market was boosted by this merger. Also, in September 2019, a leading pharmaceutical industry Acceleron pharma received approval from FDA (Food and Drug Administration) for an orphan drug called sotatercept for the treatment of pulmonary arteries hypertension. Hence, these approvals are likely to boost market growth further.

The Asia Pacific is expected to grow at the quickest rate of 5.9%. Owing to improved healthcare systems, fast economic growth, together with a huge population base. Furthermore, the high prevalence of diseases such as HIV and diabetes, which are linked to the development of PAH (Pulmonary Arterial Hypertension), supports market expansion in Asian countries. Despite a huge decline in the sales of products during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 4.9 %, during the tenure of 2021 – 2027.

The report published by Maximize encompasses the market dynamics, which could affect the market growth of the Pulmonary Arterial Hypertension Market in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Pulmonary Arterial Hypertension Market at a global level. The study is associated based on major segments and further into sub-segments, Drug Class (Prostacyclin and Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators, Endothelin Receptor Antagonist (ERA), Phosphodiesterase 5 (PDE-5)r) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2019, considering 2020 as the base year.

Lastly, the market research report provides a regional comparison and a complete country-level analysis for the Technology trends, along with the major key players- Johnson & Johnson Services, Inc.; Gilead Sciences, Inc.; United Therapeutics Corporation; GlaxoSmithKline Plc. (GSK); Pfizer, Inc.; Acceleron Pharma, Inc.; Bayer AG, Janssen Türkiye Trident, Life Sciences Ltd, PhaseBio Pharmaceuticals, Inc., Domedica, Biozeus Biopharmaceuticals

 You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Pulmonary Arterial Hypertension Market.” 



Omkar Heights,

ManikBaug, Vadgaon Bk,

Sinhagad Road, Pune – 411051,

Maharashtra, India.

+91 9607195908

Leave a Replay

Your email address will not be published. Required fields are marked *